Double-Punch CAR-T trial aims to tame tough leukemia
NCT ID NCT07201727
Summary
This early-phase study is testing a new two-step treatment for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to other therapies. Doctors will first give patients one type of engineered immune cell (CAR-T), then a second type, with the goal of controlling the cancer enough for a stem cell transplant. The main goal is to see if this sequential approach is safe and shows signs of working in up to 10 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.